68Ga-labeled radiopharmaceuticals for positron emission tomography

被引：49

作者：

Shetty D. ^{[1
]}

Lee Y.-S. ^{[1
]}

Jeong J.M. ^{[1
]}

机构：

[1] Department of Nuclear Medicine, Institute of Radiation Medicine, Seoul National University College of Medicine, Jongno-gu, Seoul 110-744

来源：

Nuclear Medicine and Molecular Imaging | 2010年 / 44卷 / 4期

关键词：

BAPEN; DOTA; Ga-68; Gallium-68; MSA; NOTA; Peptide; PET;

D O I：

10.1007/s13139-010-0056-6

中图分类号：

学科分类号：

摘要：

68Ga is a promising emerging radionuclide for positron emission tomography (PET). It is produced using a 68Ge/68Ga-generator, and thus, would enable the cyclotronindependent distribution of PET. However, new 68Galabeled radiopharmaceuticals that can replace 18F-labeled agents like [18F]fluorodeoxyglucose (FDG) are needed. Most of the 68Ga-labeled derivatives currently used are peptide agents, but the developments of other agents, such as amino acid derivatives, nitroimidazole derivatives, and glycosylated human serum albumin, are being actively pursued in many laboratories. Thus, appearance of new 68Ga-labeled radiopharmaceuticals with high impact are expected in the near future. Here, we present an overview of 68Ga-labeled agents in terms of their clinical significances and relevances to the management of certain tumors, and pertinent pre-clinical developments. © Korean Society of Nuclear Medicine 2010.

引用

页码：233 / 240

页数：7

共 63 条

[1]

Breeman W.A., Verbruggen A.M., The 68Ge/68Ga generator has high potential, but when can we use 68Ga-labelled tracers in clinical routine?, Eur J Nucl Med Mol Imaging, 34, pp. 978-981, (2007)

[2]

Ehrhardt G.J., Welch M.J., A new germanium-63/gallium-68 generator, J Nucl Med, 19, pp. 925-929, (1978)

[3]

Zhernosekov K.P., Filosofov D.V., Baum R.P., Aschoff P., Bihl H., Razbash A.A., Et al., Processing of generator-produced 68Ga for medical application, J Nucl Med, 48, pp. 1741-1748, (2007)

[4]

Antunes P., Ginj M., Zhang H., Waser B., Baum R.P., Reubi J.C., Et al., Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?, Eur J Nucl Med Mol Imaging, 34, pp. 982-993, (2007)

[5]

Buchmann I., Henze M., Engelbrecht S., Eisenhut M., Runz A., Schafer M., Et al., Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours, Eur J Nucl Med Mol Imaging, 34, pp. 1617-1626, (2007)

[6]

Gabriel M., Decristoforo C., Kendler D., Dobrozemsky G., Heute D., Uprimny C., Et al., 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT, J Nucl Med, 48, pp. 508-518, (2007)

[7]

Ambrosini V., Tomassetti P., Castellucci P., Campana D., Montini G., Rubello D., Et al., Comparison between 68Ga-DOTA-NOC and 18FDOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours, Eur J Nucl Med Mol Imaging, 35, pp. 1431-1438, (2008)

[8]

Parker D., Tumour targeting with radiolabelled macrocycle-antibody conjugates, Chem Soc Rev, 19, pp. 271-291, (1990)

[9]

Harris W.R., Pecoraro V.L., Thermodynamic binding constants for gallium transferrin, Biochemistry, 22, pp. 292-299, (1983)

[10]

Chong H.S., Ma X., Le T., Kwamena B., Milenic D.E., Brady E.D., Et al., Rational design and generation of a bimodal bifunctional ligand for antibody-targeted radiation cancer therapy, J Med Chem, 51, pp. 118-125, (2008)

← 1 2 3 4 5 6 7 →